

Somatic *STAT3* Mutations in Large Granular Lymph

New England Journal of Medicine

366, 1905-1913

DOI: [10.1056/nejmoa1114885](https://doi.org/10.1056/nejmoa1114885)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Obatoclax, Saliphenylhalamide, and Gemcitabine Inhibit Influenza A Virus Infection. <i>Journal of Biological Chemistry</i> , 2012, 287, 35324-35332.	1.6	80
2	Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. <i>Future Oncology</i> , 2012, 8, 787-801.	1.1	38
3	STATe-of-the-Art Approach: Using Oligonucleotide Decoys to Target the "Undruggable" Figure 1.. <i>Cancer Discovery</i> , 2012, 2, 670-672.	7.7	7
5	Determinants of the extent and duration of STAT3 signaling. <i>Jak-stat</i> , 2012, 1, 211-215.	2.2	19
6	Genome-Scale Technology Driven Advances to Research into Normal and Malignant Haematopoiesis. <i>Scientifica</i> , 2012, 2012, 1-11.	0.6	0
7	STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. <i>Blood</i> , 2012, 120, 3048-3057.	0.6	360
8	LGL: a disease rediscovered. <i>Blood</i> , 2012, 120, 2932-2933.	0.6	2
9	Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation. <i>Cancer Cell</i> , 2012, 22, 645-655.	7.7	150
10	Cancer genomics and pathology: <i>All Together Now</i>. <i>Pathology International</i> , 2012, 62, 647-659.	0.6	6
12	Phosphotyrosine recognition domains: the typical, the atypical and the versatile. <i>Cell Communication and Signaling</i> , 2012, 10, 32.	2.7	70
13	Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. <i>Current Opinion in Pharmacology</i> , 2012, 12, 464-470.	1.7	193
14	Dysplasia Has A Differential Diagnosis: Distinguishing Genuine Myelodysplastic Syndromes (MDS) From Mimics, Imitators, Copycats and Impostors. <i>Current Hematologic Malignancy Reports</i> , 2012, 7, 310-320.	1.2	86
15	Therapeutic modulators of STAT signalling for human diseases. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 611-629.	21.5	366
16	Next Generation Sequencing in Cancer Research. , 2013, , .		5
17	Clonal T-LGL population mimicking leukemia in Felty's syndrome"part of a continuous spectrum of T-LGL proliferations?. <i>Annals of Hematology</i> , 2013, 92, 985-987.	0.8	10
18	Vasculitis associated with large granular lymphocyte (LGL) leukemia: Presentation and treatment outcomes of 11 cases. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 362-366.	1.6	18
20	STAT Activation in Malignancies: Roles in Tumor Progression and in the Generation of Antineoplastic Effects of IFNs. <i>Journal of Interferon and Cytokine Research</i> , 2013, 33, 181-188.	0.5	7
21	Targeted Sequencing Strategies in Cancer Research. , 2013, , 137-163.		2

#	ARTICLE	IF	CITATIONS
23	Deep sequencing of the T-cell receptor repertoire in CD8+ T-large granular lymphocyte leukemia identifies signature landscapes. <i>Blood</i> , 2013, 122, 4077-4085.	0.6	62
24	STAT3exon 21 mutation is rare in common human cancers. <i>Acta Oncologica</i> , 2013, 52, 1221-1222.	0.8	4
25	Galaxy tools to study genome diversity. <i>GigaScience</i> , 2013, 2, 17.	3.3	19
26	Emerging patterns of somatic mutations in cancer. <i>Nature Reviews Genetics</i> , 2013, 14, 703-718.	7.7	442
27	Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 775-785.	1.9	36
28	Large granular lymphocyte leukemia associated with hepatitis C virus infection and B cell lymphoma: improvement after antiviral therapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 1797-1799.	0.6	8
29	JAKs and STATs in Immunity, Immunodeficiency, and Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 161-170.	13.9	738
30	Next-generation sequencing " feasibility and practicality in haematology. <i>British Journal of Haematology</i> , 2013, 160, 736-753.	1.2	54
31	Severe Growth Deficiency is Associated with STAT5b Mutations that Disrupt Protein Folding and Activity. <i>Molecular Endocrinology</i> , 2013, 27, 150-161.	3.7	15
32	Challenges in Consolidated Reporting of Hematopoietic Neoplasms. <i>Surgical Pathology Clinics</i> , 2013, 6, 795-806.	0.7	7
33	Distinguishing T-cell Large Granular Lymphocytic Leukemia from Reactive Conditions. <i>Surgical Pathology Clinics</i> , 2013, 6, 631-639.	0.7	10
34	Molecular underpinning of extranodal NK/T-cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 57-74.	0.7	64
35	Hepatocellular Benign Tumors"From Molecular Classification to Personalized Clinical Care. <i>Gastroenterology</i> , 2013, 144, 888-902.	0.6	251
36	JAK/STAT signaling in hematological malignancies. <i>Oncogene</i> , 2013, 32, 2601-2613.	2.6	465
37	Whole genome profiling and other high throughput technologies in lymphoid neoplasms"current contributions and future hopes. <i>Modern Pathology</i> , 2013, 26, S97-S110.	2.9	17
38	The Underappreciated Role of Allostery in the Cellular Network. <i>Annual Review of Biophysics</i> , 2013, 42, 169-189.	4.5	152
39	STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. <i>Journal of Hematology and Oncology</i> , 2013, 6, 82.	6.9	39
40	STAT3 mutations are highly specific for large granular lymphocytic leukemia. <i>Leukemia</i> , 2013, 27, 1598-1600.	3.3	86

#	ARTICLE	IF	CITATIONS
41	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	7.7	334
42	STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia. <i>Blood</i> , 2013, 122, 542-549.	0.6	44
43	Holistic Systems Biology Approaches to Molecular Mechanisms of Human Helper T Cell Differentiation to Functionally Distinct Subsets. <i>Scandinavian Journal of Immunology</i> , 2013, 78, 172-180.	1.3	3
44	Signal transducers and activators of transcription 3 function in lung cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2013, 9, 67.	0.3	15
45	Fibrosis and Subsequent Cytopenias Are Associated with Basic Fibroblast Growth Factor-Deficient Pluripotent Mesenchymal Stromal Cells in Large Granular Lymphocyte Leukemia. <i>Journal of Immunology</i> , 2013, 191, 3578-3593.	0.4	18
46	STAT3 mutations are frequent in CD30+ T-cell lymphomas and T-cell large granular lymphocytic leukemia. <i>Leukemia</i> , 2013, 27, 2244-2247.	3.3	68
47	Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4541-4550.	0.6	252
48	Involvement of STAT3 in immune evasion during lung tumorigenesis. <i>Oncolmmunology</i> , 2013, 2, e22653.	2.1	20
49	How should we define STAT3 as an oncogene and as a potential target for therapy?. <i>Jak-stat</i> , 2013, 2, e24716.	2.2	43
50	Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. <i>Blood Cancer Journal</i> , 2013, 3, e168-e168.	2.8	56
51	Targeting the tumor microenvironment. <i>Jak-stat</i> , 2013, 2, e23828.	2.2	140
52	STAT3 inhibitors for cancer therapy. <i>Jak-stat</i> , 2013, 2, e22882.	2.2	88
53	Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. <i>Blood</i> , 2013, 122, 3599-3606.	0.6	156
54	The genetic basis of myelodysplasia and its clinical relevance. <i>Blood</i> , 2013, 122, 4021-4034.	0.6	294
55	Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. <i>Blood</i> , 2013, 121, 3843-3854.	0.6	85
56	Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia. <i>Blood</i> , 2013, 121, 476-484.	0.6	62
57	Long-term remission of T-cell large granular lymphocyte leukemia associated with rheumatoid arthritis after rituximab therapy. <i>Blood</i> , 2013, 122, 1583-1586.	0.6	28
58	STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. <i>Blood</i> , 2013, 122, 2453-2459.	0.6	128

#	ARTICLE	IF	CITATIONS
59	Reactive and Neoplastic Large Granular Cell Proliferations in Blood and Bone Marrow. <i>The Journal of Oncopathology</i> , 2013, 1, 67-75.	0.1	0
60	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. <i>Haematologica</i> , 2013, 98, 1748-1752.	1.7	50
61	Unraveling the molecular events leading to the genesis of large granular lymphocytic leukemia reveals a new treatment strategy. <i>Haematologica</i> , 2013, 98, 159-159.	1.7	1
62	New-generation sequencing (NGS) in hematologic oncology laboratories. <i>Hematologie</i> , 2013, 19, 112-122.	0.0	2
63	A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling. <i>PLoS ONE</i> , 2013, 8, e67851.	1.1	20
64	The Spectrum of Chronic CD8+ T-Cell Expansions: Clinical Features in 14 Patients. <i>PLoS ONE</i> , 2014, 9, e91505.	1.1	4
65	Detection of the G17V RHOA Mutation in Angioimmunoblastic T-Cell Lymphoma and Related Lymphomas Using Quantitative Allele-Specific PCR. <i>PLoS ONE</i> , 2014, 9, e109714.	1.1	24
66	STAT3 as an emerging molecular target in pancreatic cancer. <i>Gastrointestinal Cancer: Targets and Therapy</i> , 2014, , 115.	5.5	4
67	Profile of pacritinib and its potential in the treatment of hematologic disorders. <i>Journal of Blood Medicine</i> , 2014, 5, 143.	0.7	21
68	Uncovering influence links in molecular knowledge networks to streamline personalized medicine. <i>Journal of Biomedical Informatics</i> , 2014, 52, 394-405.	2.5	10
69	Molecular Pathways: Interleukin-15 Signaling in Health and in Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 2044-2050.	3.2	166
70	Large granular lymphocytosis during dasatinib therapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 247-255.	1.5	43
71	Consequences of the disease-related L78R mutation for dimerization and activity of STAT3. <i>Journal of Cell Science</i> , 2014, 127, 1899-910.	1.2	26
72	Cyclophosphamide as a first-line therapy in LGL leukemia. <i>Leukemia</i> , 2014, 28, 1134-1136.	3.3	74
73	Control of gp130 expression by the mitogen-activated protein kinase ERK2. <i>Oncogene</i> , 2014, 33, 2255-2263.	2.6	17
74	Lack of common TCRA and TCRB clonotypes in CD8+TCR β ^{hi} T-cell large granular lymphocyte leukemia: a review on the role of antigenic selection in the immunopathogenesis of CD8+ T-LGL. <i>Blood Cancer Journal</i> , 2014, 4, e172-e172.	2.8	17
75	Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. <i>Leukemia</i> , 2014, 28, 417-419.	3.3	97
76	Frequent STAT5B mutations in β γ hepatosplenic T-cell lymphomas. <i>Leukemia</i> , 2014, 28, 2244-2248.	3.3	119

#	ARTICLE	IF	CITATIONS
77	Protein tyrosine phosphatases as wardens of STAT signaling. <i>Jak-stat</i> , 2014, 3, e28087.	2.2	73
78	Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. <i>Cancers</i> , 2014, 6, 926-957.	1.7	234
79	STAT3 in Cancer—Friend or Foe?. <i>Cancers</i> , 2014, 6, 1408-1440.	1.7	137
80	Activating KIRs in Chronic Lymphoproliferative Disorder of NK Cells: Protection from Viruses and Disease Induction?. <i>Frontiers in Immunology</i> , 2014, 5, 72.	2.2	22
81	Familial CD3 ⁺ large granular lymphocyte leukemia: evidence that genetic predisposition and antigen selection promote clonal cytotoxic T-cell responses. <i>Leukemia and Lymphoma</i> , 2014, 55, 1781-1787.	0.6	8
82	Role of STAT3 in lung cancer. <i>Jak-stat</i> , 2014, 3, e999503.	2.2	61
83	Allergy and risk of hematologic malignancies: Associations and mechanisms. <i>Leukemia Research</i> , 2014, 38, 1137-1144.	0.4	13
84	Treating rare lymphoproliferative malignancies: a focus on indolent large granular lymphocytic leukemia. <i>International Journal of Hematologic Oncology</i> , 2014, 3, 407-418.	0.7	0
85	Transformed aggressive β -chain variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations. <i>European Journal of Haematology</i> , 2014, 93, 260-264.	1.1	10
86	Submicroscopic genomic rearrangements change gene expression in β -cell large granular lymphocyte leukemia. <i>European Journal of Haematology</i> , 2014, 93, 143-149.	1.1	4
87	Disease-specific mutations in mature lymphoid neoplasms: Recent advances. <i>Cancer Science</i> , 2014, 105, 623-629.	1.7	14
88	Novel TBL1XR1, EPHA7 and SLFN12 mutations in a Sezary syndrome patient discovered by whole exome sequencing. <i>Experimental Dermatology</i> , 2014, 23, 366-368.	1.4	12
89	Molecular Diagnostics of T-Cell Lymphoproliferative Disorders. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 48-60.	1.0	4
90		0.1	0
91	STAT3: An Anti-Invasive Factor in Colorectal Cancer?. <i>Cancers</i> , 2014, 6, 1394-1407.	1.7	11
92	Lymphoma With Features Intermediate Between Aggressive T-Large Granular Lymphocytic Leukemia and Hepatosplenic T-Cell Lymphoma: A Diagnostic Dilemma?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e95-e100.	0.2	8
93	Mouse LSTRA leukemia as a model of human natural killer T cell and highly aggressive lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2014, 55, 706-708.	0.6	4
94	STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. <i>Leukemia</i> , 2014, 28, 248-257.	3.3	58

#	ARTICLE	IF	CITATIONS
95	The pathogenesis and treatment of large granular lymphocyte leukemia. <i>Blood Reviews</i> , 2014, 28, 87-94.	2.8	69
96	NK cell development and function – Plasticity and redundancy unleashed. <i>Seminars in Immunology</i> , 2014, 26, 114-126.	2.7	46
97	Autoimmune neutropenia. <i>Presse Medicale</i> , 2014, 43, e105-e118.	0.8	26
98	Protein mislocalization: Mechanisms, functions and clinical applications in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 13-25.	3.3	57
99	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	7.7	240
100	Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 136-154.	3.3	427
101	<i>STAT3</i> gene mutations and their association with pure red cell aplasia in large granular lymphocyte leukemia. <i>Cancer Science</i> , 2014, 105, 342-346.	1.7	67
102	Molecular monitoring in NUP214-ABL-positive T-acute lymphoblastic leukemia reveals clonal diversity and helps to guide targeted therapy. <i>Leukemia</i> , 2014, 28, 419-422.	3.3	7
103	Early lymphoid lesions: conceptual, diagnostic and clinical challenges. <i>Haematologica</i> , 2014, 99, 1421-1432.	1.7	50
104	Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. <i>Annals of Oncology</i> , 2014, 25, 2030-2035.	0.6	49
105	STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia. <i>Oncologist</i> , 2014, 19, 536-544.	1.9	55
106	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1738-1742.	3.3	90
107	Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease. <i>Nature Genetics</i> , 2014, 46, 812-814.	9.4	411
108	Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells. <i>Cancer Cell</i> , 2014, 26, 207-221.	7.7	452
109	Therapeutic Targeting of the <i>JAK/STAT</i> Pathway. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 114, 18-23.	1.2	118
110	I Walk the Line: How to Tell MDS From Other Bone Marrow Failure Conditions. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 389-399.	1.2	9
111	KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer. <i>Molecular Cancer</i> , 2014, 13, 176.	7.9	46
112	ISL-1 is overexpressed in non-Hodgkin lymphoma and promotes lymphoma cell proliferation by forming a p-STAT3/p-c-Jun/ISL-1 complex. <i>Molecular Cancer</i> , 2014, 13, 181.	7.9	24

#	ARTICLE	IF	CITATIONS
113	CD4 positive/CD8 negative/CD56 positive T cell large granular lymphocyte proliferations; clonal disorders of uncertain significance. BMC Hematology, 2014, 14, .	2.6	2
114	Uncovering the pathogenesis of large granular lymphocytic leukemia—novel <i>STAT3</i> and <i>STAT5b</i> mutations. Annals of Medicine, 2014, 46, 114-122.	1.5	62
115	Clinical Implications of Phosphorylated STAT3 Expression in <i>De Novo</i> Diffuse Large B-cell Lymphoma. Clinical Cancer Research, 2014, 20, 5113-5123.	3.2	60
116	Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells. Journal of Biological Chemistry, 2014, 289, 15969-15978.	1.6	78
117	The Challenging World of Cytopenias: Distinguishing Myelodysplastic Syndromes From Other Disorders of Marrow Failure. Oncologist, 2014, 19, 735-745.	1.9	27
118	Clinical Relevance of Sensitive and Quantitative STAT3 Mutation Analysis Using Next-Generation Sequencing in T-Cell Large Granular Lymphocytic Leukemia. Journal of Molecular Diagnostics, 2014, 16, 382-392.	1.2	18
119	Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors. Clinical Cancer Research, 2014, 20, 2051-2059.	3.2	140
120	Leptomeningeal lymphomatosis from large granular lymphocyte leukaemia. Journal of Neurology, 2014, 261, 1221-1222.	1.8	0
121	STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica, 2014, 99, e105-e105.	1.7	37
122	Take (STAT)5: jazzing up T-cell leukemia. Blood, 2014, 124, 1383-1384.	0.6	7
123	A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. Blood, 2014, 123, 1293-1296.	0.6	345
124	Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood, 2014, 124, 2370-2379.	0.6	90
125	Detection of monoclonal T populations in patients with KIR-restricted chronic lymphoproliferative disorder of NK cells. Haematologica, 2014, 99, 1826-1833.	1.7	21
127	Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3. Blood, 2015, 125, 639-648.	0.6	229
128	Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations. Blood, 2015, 125, 591-599.	0.6	436
129	Primary CNS T-cell Lymphomas. American Journal of Surgical Pathology, 2015, 39, 1719-1729.	2.1	53
130	IL-15 as a potential target in leukemia. Blood and Lymphatic Cancer: Targets and Therapy, 2015, , 55.	1.2	1
132	STAT3-Mediated Metabolic Reprograming in Cellular Transformation and Implications for Drug Resistance. Frontiers in Oncology, 2015, 5, 121.	1.3	106

#	ARTICLE	IF	CITATIONS
133	The Complex Role of STAT3 in Viral Infections. <i>Journal of Immunology Research</i> , 2015, 2015, 1-9.	0.9	65
134	T-cell large granular lymphocytic leukemia. <i>Hematologie</i> , 2015, 21, 303-310.	0.0	1
135	High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). <i>Leukemia</i> , 2015, 29, 1928-1938.	3.3	36
136	Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase. <i>Annals of Oncology</i> , 2015, 26, 1005-1011.	0.6	25
137	Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice. <i>Leukemia</i> , 2015, 29, 2050-2061.	3.3	14
139	Cell-cell and cell-matrix adhesion in survival and metastasis: Stat3 versus Akt. <i>Biomolecular Concepts</i> , 2015, 6, 383-399.	1.0	33
140	Increased STAT3 phosphorylation on CD27 + B-cells from common variable immunodeficiency disease patients. <i>Clinical Immunology</i> , 2015, 161, 77-88.	1.4	9
141	Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. <i>Annals of Oncology</i> , 2015, 26, 998-1005.	0.6	138
142	Emergence of a STAT3 mutated NK clone in LGL leukemia. <i>Leukemia Research Reports</i> , 2015, 4, 4-7.	0.2	8
143	Activating mutations of STAT5B and STAT3 in lymphomas derived from $\gamma\delta$ T or NK cells. <i>Nature Communications</i> , 2015, 6, 6025.	5.8	334
144	The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. <i>Annual Review of Medicine</i> , 2015, 66, 311-328.	5.0	1,074
145	The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. <i>British Journal of Cancer</i> , 2015, 113, 365-371.	2.9	460
146	Large granular lymphocyte leukemia: clinical background, molecular pathogenesis and treatment. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 859-867.	0.5	0
147	Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 499-506.	3.2	42
148	Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). <i>Leukemia</i> , 2015, 29, 886-894.	3.3	92
149	T-cell lymphoma: Microenvironment-related biomarkers. <i>Seminars in Cancer Biology</i> , 2015, 34, 46-51.	4.3	27
150	Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , 2015, 27, 516-532.	7.7	378
151	Coexistence of ALK-anaplastic large cell lymphoma and CD4+ T cell large granular lymphocytic leukemia. <i>Annals of Hematology</i> , 2015, 94, 539-540.	0.8	0

#	ARTICLE	IF	CITATIONS
152	STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2015, 8, 29-41.	1.0	32
153	Molecular deregulation of signaling in lymphoid tumors. <i>European Journal of Haematology</i> , 2015, 95, 257-269.	1.1	6
154	Pathology of T-Cell Lymphomas: Diagnosis and Biomarker Discovery. <i>Cancer Treatment and Research</i> , 2015, 165, 51-95.	0.2	4
155	Protein Kinase CK2 Cellular Function in Normal and Disease States. , 2015, , .		6
156	<i>PARD3</i> Inactivation in Lung Squamous Cell Carcinomas Impairs STAT3 and Promotes Malignant Invasion. <i>Cancer Research</i> , 2015, 75, 1287-1297.	0.4	44
157	HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in <i>BRAF</i> -Mutant Colorectal Cancer by Downregulation of c-FLIPL. <i>Clinical Cancer Research</i> , 2015, 21, 3230-3240.	3.2	53
158	Ras Signaling Is a Key Determinant for Metastatic Dissemination and Poor Survival of Luminal Breast Cancer Patients. <i>Cancer Research</i> , 2015, 75, 4960-4972.	0.4	48
159	HCS Campaign to Identify Selective Inhibitors of IL-6-Induced STAT3 Pathway Activation in Head and Neck Cancer Cell Lines. <i>Assay and Drug Development Technologies</i> , 2015, 13, 356-376.	0.6	24
160	High rate of both hematopoietic and solid tumors associated with large granular lymphocyte leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 503-504.	0.6	18
161	STX 11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas. <i>Cancer Science</i> , 2015, 106, 1455-1462.	1.7	17
162	JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. <i>Haematologica</i> , 2015, 100, 1240-1253.	1.7	55
163	Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. <i>Leukemia</i> , 2015, 29, 2427-2429.	3.3	57
164	Mature T-cell leukemias: Molecular and Clinical Aspects. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 421-428.	1.2	4
165	Molecular Pathogenesis of Peripheral T Cell Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 429-437.	1.2	13
166	The impact of next generation sequencing technologies on haematological research – A review. <i>Pathogenesis</i> , 2015, 2, 9-16.	0.8	19
167	The Ying and Yang of STAT3 in Human Disease. <i>Journal of Clinical Immunology</i> , 2015, 35, 615-623.	2.0	130
168	Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia. <i>Cancer Biology and Therapy</i> , 2015, 16, 1830-1840.	1.5	29
169	Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies. <i>Blood Reviews</i> , 2015, 29, 405-415.	2.8	38

#	ARTICLE	IF	CITATIONS
170	Clinicopathologic, Immunophenotypic, Cytogenetic, and Molecular Features of $\hat{I}^{\beta 1}$ T-Cell Large Granular Lymphocytic Leukemia: An Analysis of 14 Patients Suggests Biologic Differences With $\hat{I}^{\beta 1}$ T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2015, 144, 607-619.	0.4	34
171	The mutational landscape of cutaneous T cell lymphoma and SÅ©zary syndrome. <i>Nature Genetics</i> , 2015, 47, 1465-1470.	9.4	322
172	Mutations in the linker domain affect phospho-STAT3 function and suggest targets for interrupting STAT3 activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14811-14816.	3.3	34
173	The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. <i>Haematologica</i> , 2015, 100, 91-99.	1.7	88
174	Assessment of clonality in T-cell large granular lymphocytic leukemia: flow cytometric T cell receptor V \hat{I}^2 repertoire and T cell receptor gene rearrangement. <i>Leukemia and Lymphoma</i> , 2015, 56, 324-331.	0.6	8
176	Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer. <i>Oncogene</i> , 2015, 34, 1341-1353.	2.6	139
177	Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 586-597.	3.3	111
178	Dual Roles of IL-15 in Cancer Biology. <i>Journal of Cytokine Biology</i> , 2016, 01, .	1.5	0
179	Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 31-34.	1.0	8
180	Successful Treatment of Genetically Profiled Pediatric Extranodal NK/Tâ€Cell Lymphoma Targeting Oncogenic <i><i><sc>STAT3</sc></i> Mutation. <i>Pediatric Blood and Cancer</i> , 2016, 63, 727-730.	0.8	7
181	Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)â€Resistant CML Lines While Circumventing Pharmacokinetic Liabilities. <i>ChemMedChem</i> , 2016, 11, 850-861.	1.6	23
182	Signal transducer and activator of transcription 3. <i>Current Opinion in Hematology</i> , 2016, 23, 23-27.	1.2	56
183	Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of <i><i><sc>STAT3</sc></i> mutations. <i>British Journal of Haematology</i> , 2016, 172, 937-946.	1.2	16
184	Lymph Node Fine-Needle Cytology: Beyond Flow Cytometry. <i>Acta Cytologica</i> , 2016, 60, 372-384.	0.7	19
185	WP1066 exhibits antitumor efficacy in nasal-type natural killer/T-cell lymphoma cells through downregulation of the STAT3 signaling pathway. <i>Oncology Reports</i> , 2016, 36, 2868-2874.	1.2	12
186	High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. <i>Blood</i> , 2016, 128, 2465-2468.	0.6	86
187	The JAKâ€STATâ€SOCS Signaling Cascade. , 2016, , 136-152.		4
188	Mature CD8 + Tâ€cell clonal expansion in the oral cavity and digestive tract: a severe lymphoid malignancy that mimics Crohn's disease. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 1088-1090.	0.2	1

#	ARTICLE	IF	CITATIONS
189	Alemtuzumab in T-cell large granular lymphocyte leukaemia. <i>Lancet Haematology</i> , 2016, 3, e4-e5.	2.2	2
192	Moderate-dose cyclophosphamide in the treatment of relapsed/refractory T-cell large granular lymphocytic leukemia-associated pure red cell aplasia. <i>Hematology</i> , 2016, 21, 138-143.	0.7	7
193	Cytotoxic T cells go awry in inclusion body myositis. <i>Brain</i> , 2016, 139, 1312-1314.	3.7	14
194	Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. <i>Leukemia</i> , 2016, 30, 1204-1208.	3.3	62
195	Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. <i>Blood</i> , 2016, 127, 948-951.	0.6	52
196	The 2016 revision of the World Health Organization classification of lymphoid neoplasms. <i>Blood</i> , 2016, 127, 2375-2390.	0.6	5,965
197	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. <i>Haematologica</i> , 2016, 101, 1002-1009.	1.7	43
198	Interleukin-15-Dependent T-Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease. <i>Immunity</i> , 2016, 45, 610-625.	6.6	131
199	Historical Development of STAT3 Inhibitors and Early Results in Clinical Trials. <i>Cancer Drug Discovery and Development</i> , 2016, , 69-94.	0.2	1
200	STAT Inhibitors in Cancer. <i>Cancer Drug Discovery and Development</i> , 2016, , .	0.2	1
201	Molecular Pathology. <i>Surgical Pathology Clinics</i> , 2016, 9, 489-521.	0.7	3
202	Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. <i>Cancer</i> , 2016, 122, 1398-1407.	2.0	47
203	Recurrent alterations of <i>TNFAIP3</i> (A20) in T-cell large granular lymphocytic leukemia. <i>International Journal of Cancer</i> , 2016, 138, 121-124.	2.3	36
204	Cell size variations of large granular lymphocyte leukemia: Implication of a small cell subtype of granular lymphocyte leukemia with STAT3 mutations. <i>Leukemia Research</i> , 2016, 45, 8-13.	0.4	13
205	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. <i>Blood</i> , 2016, 128, 1490-1502.	0.6	255
206	Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. <i>Blood</i> , 2016, 127, 2439-2450.	0.6	40
207	Candidate driver genes involved in genome maintenance and DNA repair in S�zary syndrome. <i>Blood</i> , 2016, 127, 3387-3397.	0.6	96
208	Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 705-712.	0.2	3

#	ARTICLE	IF	CITATIONS
209	Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. <i>Blood Cancer Journal</i> , 2016, 6, e397-e397.	2.8	45
210	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. <i>Nature Communications</i> , 2016, 7, 12602.	5.8	146
211	Donor-Derived T-Cell Large Granular Lymphocytic Leukemia in a Patient With Peripheral T-Cell Lymphoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 939-944.	2.3	9
212	Genetics of Cutaneous T Cell Lymphoma: From Bench to Bedside. <i>Current Treatment Options in Oncology</i> , 2016, 17, 33.	1.3	51
213	Validation and Implementation of a Custom Next-Generation Sequencing Clinical Assay for Hematologic Malignancies. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 507-515.	1.2	144
214	Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. <i>Leukemia</i> , 2016, 30, 2245-2247.	3.3	75
215	Distinct mutations at the same positions of STAT3 cause either loss or gain of function. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1222-1224.e2.	1.5	23
216	Rare autoimmune disorders with Mendelian inheritance. <i>Autoimmunity</i> , 2016, 49, 285-297.	1.2	4
217	JAK-STAT signaling in cancer: From cytokines to non-coding genome. <i>Cytokine</i> , 2016, 87, 26-36.	1.4	186
218	TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies. <i>Cytokine</i> , 2016, 82, 52-57.	1.4	58
219	Association of inclusion body myositis with T cell large granular lymphocytic leukaemia. <i>Brain</i> , 2016, 139, 1348-1360.	3.7	93
220	Phosphorylated STAT3 expression in hematopoietic stem cell transplant-associated large granular lymphocytic leukemia. <i>Bone Marrow Transplantation</i> , 2016, 51, 741-743.	1.3	5
221	The crossroads of autoimmunity and immunodeficiency: Lessons from polygenic traits and monogenic defects. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 3-17.	1.5	100
222	Immune deficiency vs. immune excess in inflammatory bowel diseases—STAT3 as a rheo-STAT of intestinal homeostasis. <i>Journal of Leukocyte Biology</i> , 2016, 99, 57-66.	1.5	9
223	The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 53-65.	1.6	80
224	JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 88-96.	1.6	29
225	Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. <i>Expert Review of Hematology</i> , 2017, 10, 239-249.	1.0	104
226	THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. <i>Nature Communications</i> , 2017, 8, 14290.	5.8	74

#	ARTICLE	IF	CITATIONS
227	Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options. <i>Expert Review of Hematology</i> , 2017, 10, 251-258.	1.0	23
228	JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics. <i>Molecular and Cellular Endocrinology</i> , 2017, 451, 66-70.	1.6	22
229	JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. <i>Drugs</i> , 2017, 77, 521-546.	4.9	711
230	LGL leukemia: from pathogenesis to treatment. <i>Blood</i> , 2017, 129, 1082-1094.	0.6	227
231	Genomic landscape characterization of large granular lymphocyte leukemia with a systems genetics approach. <i>Leukemia</i> , 2017, 31, 1243-1246.	3.3	33
232	Targeted strategies directed at the molecular defect: Toward precision medicine for select primary immunodeficiency disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 715-723.	1.5	54
233	Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. <i>Annual Review of Immunology</i> , 2017, 35, 533-550.	9.5	139
234	An Activating STAT3 Mutation Causes Neonatal Diabetes through Premature Induction of Pancreatic Differentiation. <i>Cell Reports</i> , 2017, 19, 281-294.	2.9	94
235	Immune and myodegenerative pathomechanisms in inclusion body myositis. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 422-445.	1.7	41
237	Somatic mutations in clonally expanded cytotoxic T lymphocytes in patients with newly diagnosed rheumatoid arthritis. <i>Nature Communications</i> , 2017, 8, 15869.	5.8	83
238	STAT3 in cancer: A double edged sword. <i>Cytokine</i> , 2017, 98, 42-50.	1.4	133
239	Cytotoxic T cells in chronic idiopathic neutropenia express restricted antigen receptors. <i>Leukemia and Lymphoma</i> , 2017, 58, 2926-2933.	0.6	6
240	STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds. <i>Clinical Immunology</i> , 2017, 181, 32-42.	1.4	48
241	Diagnosis and classification of hematologic malignancies on the basis of genetics. <i>Blood</i> , 2017, 130, 410-423.	0.6	163
243	Cytokine receptor signaling is required for the survival of ALK ⁺ anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 3975-3980.	3.3	68
244	Short Stature in a Boy with Multiple Early-Onset Autoimmune Conditions due to a <i>JAK/STAT3</i> Activating Mutation: Could Intracellular Growth Hormone Signalling Be Compromised?. <i>Hormone Research in Paediatrics</i> , 2017, 88, 160-166.	0.8	31
246	Novel JAK3-Activating Mutations in Extranodal NK/T-Cell Lymphoma, Nasal Type. <i>American Journal of Pathology</i> , 2017, 187, 980-986.	1.9	44
247	Mechanisms and consequences of JAK-STAT signaling in the immune system. <i>Nature Immunology</i> , 2017, 18, 374-384.	7.0	870

#	ARTICLE	IF	CITATIONS
248	Somatic STAT5b gain-of-function mutations in early onset nonclonal eosinophilia, urticaria, dermatitis, and diarrhea. <i>Blood</i> , 2017, 129, 650-653.	0.6	74
249	A new molecular paradigm in mycosis fungoides and SÅ©zary syndrome. <i>Seminars in Diagnostic Pathology</i> , 2017, 34, 15-21.	1.0	25
250	A novel class of somatic mutations in blood detected preferentially in CD8 + cells. <i>Clinical Immunology</i> , 2017, 175, 75-81.	1.4	35
251	The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 295-300.	0.7	7
252	Effect of fluorinated tetrahydrocarbazole derivatives on the enzymes of oxidative deamination of biogenic amines and on the process of lipid peroxidation. <i>Russian Chemical Bulletin</i> , 2017, 66, 870-874.	0.4	3
253	Novel molecular defects associated with very early-onset inflammatory bowel. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 317-324.	1.1	6
254	Signal transducer and activator of transcription gain-of-function primary immunodeficiency/immunodysregulation disorders. <i>Current Opinion in Pediatrics</i> , 2017, 29, 711-717.	1.0	31
255	Do STAT3 inhibitors have potential in the future for cancer therapy?. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 883-887.	1.9	191
256	Pathophysiology of Acquired Bone Marrow Failure. , 2017, , 13-33.		0
257	Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy. <i>Kidney International Reports</i> , 2017, 2, 1194-1207.	0.4	49
258	Distinguishing Between Hepatosplenic T-cell Lymphoma and Tâ€³ T-cell Large Granular Lymphocytic Leukemia. <i>American Journal of Surgical Pathology</i> , 2017, 41, 82-93.	2.1	42
259	TYK2-induced phosphorylation of Y640 suppresses STAT3 transcriptional activity. <i>Scientific Reports</i> , 2017, 7, 15919.	1.6	13
260	Monitoring therapy responses at the leukemic subclone level by ultra-deep amplicon resequencing in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 1048-1058.	3.3	11
261	Vitamin D in hematological disorders and malignancies. <i>European Journal of Haematology</i> , 2017, 98, 187-197.	1.1	54
262	Molecular Biology of Leukemias. , 2017, , 505-559.		0
263	Concurrent STAT3, DNMT3A, and TET2 mutations in Tâ€œLGL leukemia with molecularly distinct clonal hematopoiesis of indeterminate potential. <i>American Journal of Hematology</i> , 2017, 92, E6-E8.	2.0	16
264	STAT mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases. <i>Journal of Leukocyte Biology</i> , 2017, 101, 29-38.	1.5	59
265	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 301-309.	3.3	61

#	ARTICLE	IF	CITATIONS
266	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 51-57.	3.3	42
267	Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. <i>Molecular Neurobiology</i> , 2017, 54, 5780-5797.	1.9	52
268	Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. <i>Cancer Biology and Therapy</i> , 2017, 18, 290-303.	1.5	26
270	Chronic neutropenia in LGL leukemia and rheumatoid arthritis. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 181-186.	0.9	25
271	Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1786-1789.	2.5	13
272	STAT3 in Pancreatic Cancer Metastasis. , 2017, , 351-361.		1
273	IL-10-mediated signals act as a switch for lymphoproliferation in Human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. <i>PLoS Pathogens</i> , 2017, 13, e1006597.	2.1	36
274	Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCR β ^{hi} T cell large granular lymphocyte leukemia. <i>PLoS ONE</i> , 2017, 12, e0175670.	1.1	11
275	Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias. <i>Internal Medicine</i> , 2017, 56, 1759-1769.	0.3	29
276	Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL). <i>BMC Infectious Diseases</i> , 2017, 17, 797.	1.3	6
277	Mature T-Cell Neoplasms and Natural Killer-Cell Malignancies. , 0, , 140-160.		0
278	Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. <i>Cancer Research</i> , 2018, 78, 2407-2418.	0.4	60
279	Mutations in the signal transducer and activator of transcription family of genes in cancer. <i>Cancer Science</i> , 2018, 109, 926-933.	1.7	69
280	Aggressive natural killer-cell leukemia—mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. <i>Nature Communications</i> , 2018, 9, 1567.	5.8	107
281	Droplet digital polymerase chain reaction assay and peptide nucleic acid-locked nucleic acid clamp method for <i>RHOA</i> mutation detection in angioimmunoblastic T-cell lymphoma. <i>Cancer Science</i> , 2018, 109, 1682-1689.	1.7	16
282	Inhibitors of the JAK/STAT Pathway, with a Focus on Ruxolitinib and Similar Agents. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 107-134.	0.1	1
283	Dual JAK1 and STAT3 mutations in a breast implant-associated anaplastic large cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 505-511.	1.4	54
284	Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 2454-2465.	0.6	167

#	ARTICLE	IF	CITATIONS
285	Targeting the IL-6/JAK/STAT3 signalling axis in cancer. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 234-248.	12.5	1,789
286	ADA2 deficiency: Clonal lymphoproliferation in a subset of patients. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1534-1537.e8.	1.5	71
287	Chronic lymphoproliferative disorder of NK cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. <i>European Journal of Haematology</i> , 2018, 100, 444-454.	1.1	17
288	Large granular lymphocyte cells and immune dysregulation diseases – the chicken or the egg?. <i>Haematologica</i> , 2018, 103, 193-194.	1.7	5
289	Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-V β 2+ expansions. <i>Scientific Reports</i> , 2018, 8, 2534.	1.6	2
290	STAT3 mutation and its clinical and histopathologic correlation in T-cell large granular lymphocytic leukemia. <i>Human Pathology</i> , 2018, 73, 74-81.	1.1	49
291	Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors. <i>Human Pathology</i> , 2018, 74, 5-16.	1.1	77
292	SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia. <i>Leukemia</i> , 2018, 32, 890-899.	3.3	29
293	Autoimmunity and primary immunodeficiency: two sides of the same coin?. <i>Nature Reviews Rheumatology</i> , 2018, 14, 7-18.	3.5	103
294	TRAIL mediates and sustains constitutive NF- κ B activation in LGL leukemia. <i>Blood</i> , 2018, 131, 2803-2815.	0.6	35
295	Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. <i>Blood</i> , 2018, 131, 2262-2266.	0.6	77
296	<i>STAT3</i> mutations are not sufficient to induce large granular lymphocytic leukaemia in mice. <i>British Journal of Haematology</i> , 2018, 180, 911-915.	1.2	16
297	Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). <i>Leukemia and Lymphoma</i> , 2018, 59, 416-422.	0.6	72
298	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2018, 131, 215-225.	0.6	124
299	Cytokines in Cancer Immunotherapy. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a028472.	2.3	305
300	Rational management approach to pure red cell aplasia. <i>Haematologica</i> , 2018, 103, 221-230.	1.7	57
301	Somatic <i>STAT3</i> mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. <i>Haematologica</i> , 2018, 103, 304-312.	1.7	50
302	Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/PML-RARA. <i>Blood</i> , 2018, 131, 935-939.	0.6	22

#	ARTICLE	IF	CITATIONS
303	New Insights into Lymphoma Pathogenesis. Annual Review of Pathology: Mechanisms of Disease, 2018, 13, 193-217.	9.6	27
304	Integrated genomic analysis identifies deregulated JAK/STAT-MYC-biosynthesis axis in aggressive NK-cell leukemia. Cell Research, 2018, 28, 172-186.	5.7	62
305	Cucurbitacin I inhibits STAT3, but enhances STAT1 signaling in human cancer cells in vitro through disrupting actin filaments. Acta Pharmacologica Sinica, 2018, 39, 425-437.	2.8	31
306	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. Leukemia, 2018, 32, 774-787.	3.3	75
307	T-cell large granular lymphocytic leukemia associated with renal cell carcinoma. Medicine (United Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	2
308	Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 616-625.	1.8	73
309	Molecular Hematopathology. , 2018, , 712-760.e18.		4
310	Definition of a minimal genes set for mature lymphoid blood diseases. Hematologie, 2018, 24, 27-59.	0.0	4
312	Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. Cytokine, 2018, 111, 551-562.	1.4	21
313	Apport du sÃ©quenÃ§age haut dÃ©bit dans la prise en charge des hÃ©mopathies lymphoÃ©des. Revue Francophone Des Laboratoires, 2018, 2018, 75-80.	0.0	0
314	STAT3 is constitutively activated in chronic active Epstein-Barr virus infection and can be a therapeutic target. Oncotarget, 2018, 9, 31077-31089.	0.8	37
315	Genetic Aspects of Hematopoietic Malignancies. , 2018, , 201-234.		1
316	The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. Cancers, 2018, 10, 327.	1.7	94
317	How I use molecular genetic tests to evaluate patients who have or may have myelodysplastic syndromes. Blood, 2018, 132, 1657-1663.	0.6	32
318	Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. Blood Advances, 2018, 2, 481-491.	2.5	41
319	Frequent STAT3 mutations in CD8+ T cells from patients with pure red cell aplasia. Blood Advances, 2018, 2, 2704-2712.	2.5	38
320	Diagnosis and management of chronic and refractory immune cytopenias in children, adolescents, and young adults. Pediatric Blood and Cancer, 2018, 65, e27260.	0.8	13
321	Mixed-phenotype large granular lymphocytic leukemia: a rare subtype in the large granular lymphocytic leukemia spectrum. Human Pathology, 2018, 81, 96-104.	1.1	9

#	ARTICLE	IF	CITATIONS
322	Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation. <i>Blood Cancer Journal</i> , 2018, 8, 51.	2.8	20
323	Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?. , 2018, 191, 74-91.		105
324	Acquired Disorders of Red Cell, White Cell, and Platelet Production. , 2018, , 425-444.e5.		2
326	Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. <i>Blood</i> , 2018, 132, 1146-1158.	0.6	218
327	Neutrophilic Leukocytosis, Neutropenia, Monocytosis, and Monocytopenia. , 2018, , 675-681.		4
329	Signal Transducer and Activator of Transcription 3 Control of Human T and B Cell Responses. <i>Frontiers in Immunology</i> , 2018, 9, 168.	2.2	50
330	Transcriptional Regulation of Emergency Granulopoiesis in Leukemia. <i>Frontiers in Immunology</i> , 2018, 9, 481.	2.2	14
331	Bacille Calmetteâ€“Guerin Complications in Newly Described Primary Immunodeficiency Diseases: 2010â€“2017. <i>Frontiers in Immunology</i> , 2018, 9, 1423.	2.2	20
332	Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. <i>Journal of Leukocyte Biology</i> , 2018, 104, 499-514.	1.5	122
333	The 2017 WHO update on mature Tâ€“and natural killer (NK) cell neoplasms. <i>International Journal of Laboratory Hematology</i> , 2018, 40, 97-103.	0.7	51
334	Frequent Mutations in Natural Killer/T Cell Lymphoma. <i>Cellular Physiology and Biochemistry</i> , 2018, 49, 1-16.	1.1	29
335	Genomic analysis reveals recurrent deletion of JAKâ€“STAT signaling inhibitors <i>HNRNP</i> and <i>SOCS1</i> in mycosis fungoides. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 653-664.	1.5	56
336	Restoring the Long Noncoding RNA MEG3 Indicates a Potential Role for JAK-STAT Signaling in Chronic Myeloid Leukemia. <i>EBioMedicine</i> , 2018, 35, 24.	2.7	1
337	â€“Do We Know Jackâ€“About JAK? A Closer Look at JAK/STAT Signaling Pathway. <i>Frontiers in Oncology</i> , 2018, 8, 287.	1.3	283
338	STAT3: a multifaceted oncoprotein. <i>Growth Factors</i> , 2018, 36, 1-14.	0.5	131
339	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	0.6	132
340	ZNF341 controls STAT3 expression and thereby immunocompetence. <i>Science Immunology</i> , 2018, 3, .	5.6	113
341	T- and NK-Cell Lymphocytosis. , 2018, , 281-328.		0

#	ARTICLE	IF	CITATIONS
342	Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. <i>Blood</i> , 2018, 132, 544-547.	0.6	99
343	Diagnosis of NK and cytotoxic T-cell disorders: a review. <i>Diagnostic Histopathology</i> , 2018, 24, 257-266.	0.2	1
344	Acquired and germline predisposition to bone marrow failure: Diagnostic features and clinical implications. <i>Seminars in Hematology</i> , 2019, 56, 69-82.	1.8	45
345	Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 254-257.	0.6	0
346	Role of Next Generation Sequencing (NGS) in Hematological Disorders. , 2019, , 491-502.		0
347	Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e57.	0.6	3
348	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms. <i>American Journal of Clinical Pathology</i> , 2019, 152, 277-301.	0.4	6
349	Phosphorylated STAT3 expression predicts better prognosis in smoldering type of adult T-cell leukemia/lymphoma. <i>Cancer Science</i> , 2019, 110, 2982-2991.	1.7	13
350	Arthritis in Two Patients With Partial Recombination Activating Gene Deficiency. <i>Frontiers in Pediatrics</i> , 2019, 7, 235.	0.9	11
351	Large Granular Lymphocyte Leukemia. <i>Hematologic Malignancies</i> , 2019, , 167-179.	0.2	0
352	Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 553-574.	0.9	2
353	Peripheral T-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 657-668.	0.9	7
354	Stabilizing stretch reflexes are modulated independently from the rapid release of perturbation-triggered motor plans. <i>Scientific Reports</i> , 2019, 9, 13926.	1.6	8
355	RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment. <i>Experimental and Molecular Pathology</i> , 2019, 110, 104294.	0.9	7
356	TYK2: An Upstream Kinase of STATs in Cancer. <i>Cancers</i> , 2019, 11, 1728.	1.7	41
357	STAT3 Dysregulation in Mature T and NK Cell Lymphomas. <i>Cancers</i> , 2019, 11, 1711.	1.7	23
358	A Potent and Selective Small-Molecule Degradator of STAT3 Achieves Complete Tumor Regression In Vivo. <i>Cancer Cell</i> , 2019, 36, 498-511.e17.	7.7	364
359	Structural Implications of STAT3 and STAT5 SH2 Domain Mutations. <i>Cancers</i> , 2019, 11, 1757.	1.7	45

#	ARTICLE	IF	CITATIONS
360	Somatic Variants: New Kids on the Block in Human Immunogenetics. <i>Trends in Genetics</i> , 2019, 35, 935-947.	2.9	29
361	<p>Pathophysiologic Mechanisms And Management Of Large Granular Lymphocytic Leukemia Associated Pure Red Cell Aplasia</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8229-8240.	1.0	12
362	Synergistic effect of STAT3â€targeted small interfering RNA and AZD0530 against glioblastoma inî¿½vitro and inî¿½vivo. <i>Molecular Medicine Reports</i> , 2019, 20, 3625-3632.	1.1	3
363	Influenza Virus-Induced Robust Expression of SOCS3 Contributes to Excessive Production of IL-6. <i>Frontiers in Immunology</i> , 2019, 10, 1843.	2.2	48
364	New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia. <i>Advances in Biological Regulation</i> , 2019, 74, 100649.	1.4	17
365	Epigenetic downregulation of STAT6 increases HIF-1Î± expression via mTOR/S6K/S6, leading to enhanced hypoxic viability of glioma cells. <i>Acta Neuropathologica Communications</i> , 2019, 7, 149.	2.4	14
366	STAT3 and STAT5 Activation in Solid Cancers. <i>Cancers</i> , 2019, 11, 1428.	1.7	71
367	Phospho-Ser727 triggers a multistep inactivation of STAT3 by rapid dissociation of pY705â€SH2 through C-terminal tail modulation. <i>International Immunology</i> , 2020, 32, 73-88.	1.8	15
368	JAK/STAT signaling in stem cells and regeneration: from<i>Drosophila</i>to vertebrates. <i>Development (Cambridge)</i> , 2019, 146, .	1.2	140
369	T cell large granular lymphocyte leukemia and chronic NK lymphocytosis. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 207-216.	0.7	37
370	Genomics of LGL leukemia and select other rare leukemia/lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 196-206.	0.7	13
371	Posttranslational Modifications Associated With Cancer and Their Therapeutic Implications. , 2019, , 203-227.		1
372	Contribution of STAT3 and RAD23B in Primary SÃ©zary Cells to Histone Deacetylase Inhibitor FK228 Resistance. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1975-1984.e2.	0.3	9
375	STAT3 mutations in natural killer cells are associated with cytopenia in patients with chronic lymphoproliferative disorder of natural killer cells. <i>International Journal of Hematology</i> , 2019, 109, 563-571.	0.7	21
376	Subclonal STAT3 mutations solidify clonal dominance. <i>Blood Advances</i> , 2019, 3, 917-921.	2.5	28
377	Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 570-576.	1.2	18
379	JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. <i>Cancers</i> , 2019, 11, 2002.	1.7	369
380	T-cell large granular lymphocytic (LGL) leukemia consists of CD4⁺/CD8^{dim} and CD4⁻/CD8⁺ LGL populations in association with immune thrombocytopenia, autoimmune neutropenia, and monoclonal B-cell lymphocytosis. <i>Journal of Clinical and Experimental Hematopathology: ICEH</i> , 2019, 59, 202-206.	0.3	3

#	ARTICLE	IF	CITATIONS
381	In Chronic Lymphocytic Leukemia the JAK2/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. <i>Cancers</i> , 2019, 11, 1939.	1.7	39
382	Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia. <i>Leukemia</i> , 2019, 33, 415-425.	3.3	65
383	A robust pipeline with high replication rate for detection of somatic variants in the adaptive immune system as a source of common genetic variation in autoimmune disease. <i>Human Molecular Genetics</i> , 2019, 28, 1369-1380.	1.4	16
384	Therapeutically exploiting STAT3 activity in cancer " using tissue repair as a road map. <i>Nature Reviews Cancer</i> , 2019, 19, 82-96.	12.8	354
385	Novel STAT3 Inhibitor LDOC1 Targets Phospho-JAK2 for Degradation by Interacting with LNX1 and Regulates the Aggressiveness of Lung Cancer. <i>Cancers</i> , 2019, 11, 63.	1.7	26
386	Activating mutations of the gp130/JAK/STAT pathway in human diseases. <i>Advances in Protein Chemistry and Structural Biology</i> , 2019, 116, 283-309.	1.0	24
387	Dysfunction of immune system in the development of large granular lymphocyte leukemia. <i>Hematology</i> , 2019, 24, 139-147.	0.7	21
388	IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective \hat{I}^3 -chain cytokines, decreases leukemic T-cell viability. <i>Leukemia</i> , 2019, 33, 1243-1255.	3.3	40
389	Molecular pathogenesis of acquired aplastic anemia. <i>European Journal of Haematology</i> , 2019, 102, 103-110.	1.1	25
390	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	1.7	27
392	STAT3, tumor microenvironment, and microvessel density in diffuse large B cell lymphomas. <i>Leukemia and Lymphoma</i> , 2020, 61, 567-574.	0.6	19
393	Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients. <i>Leukemia</i> , 2020, 34, 1116-1124.	3.3	49
394	What is new in mature T-cell leukemias?. <i>Seminars in Diagnostic Pathology</i> , 2020, 37, 72-78.	1.0	1
395	The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 47-70.	157.7	45
396	Prenatal Autoimmune Disease, Multisystem, Infantile Onset-like Phenotype and Proximal Renal Tubular Dysplasia Associated With STAT3 Mutation. <i>Pediatric and Developmental Pathology</i> , 2020, 23, 306-311.	0.5	2
397	Revisiting signal transducer and activator of transcription 3 (STAT3) as an anticancer target and its inhibitor discovery: Where are we and where should we go?. <i>European Journal of Medicinal Chemistry</i> , 2020, 187, 111922.	2.6	56
398	STAT3 Activation and Oncogenesis in Lymphoma. <i>Cancers</i> , 2020, 12, 19.	1.7	49
399	Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity. <i>Cancers</i> , 2020, 12, 24.	1.7	53

#	ARTICLE	IF	CITATIONS
400	<p>Simultaneous Presentation of Leukemic Non-Nodal Mantle Cell Lymphoma and Gamma-Delta T-Large Granular Lymphocytic Leukemia in a Patient with Rheumatoid Arthritis</p>. Cancer Management and Research, 2020, Volume 12, 9449-9457.	0.9	3
401	Routine next generation sequencing of lymphoid malignancies: clinical utility and challenges from a 3-Year practical experience. Leukemia and Lymphoma, 2020, 61, 2568-2583.	0.6	10
402	STAT3 and STAT5B Mutations in T/NK-Cell Chronic Lymphoproliferative Disorders of Large Granular Lymphocytes (LGL): Association with Disease Features. Cancers, 2020, 12, 3508.	1.7	34
403	Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma in Asia Frequently Shows SETD2 Alterations. Cancers, 2020, 12, 3539.	1.7	22
404	Hepatosplenic T-cell lymphoma: a rare but challenging entity. Blood, 2020, 136, 2018-2026.	0.6	52
405	<p>Atypical Mature T-Cell Neoplasms: The Relevance of the Role of Flow Cytometry</p>. OncoTargets and Therapy, 2020, Volume 13, 7605-7614.	1.0	2
406	Somatic Mutations in <i>UBA1</i> and Severe Adult-Onset Autoinflammatory Disease. New England Journal of Medicine, 2020, 383, 2628-2638.	13.9	580
407	Large granular lymphocyte leukemia serum and corresponding hematological parameters reveal unique cytokine and sphingolipid biomarkers and associations with STAT3 mutations. Cancer Medicine, 2020, 9, 6533-6549.	1.3	10
408	Selective inhibition of STAT3 signaling using monobodies targeting the coiled-coil and N-terminal domains. Nature Communications, 2020, 11, 4115.	5.8	36
409	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. Frontiers in Immunology, 2020, 11, 578848.	2.2	11
410	Trichothecin Inhibits Cancer-Related Features in Colorectal Cancer Development by Targeting STAT3. Molecules, 2020, 25, 2306.	1.7	10
411	Somatic mTOR mutation in clonally expanded T lymphocytes associated with chronic graft versus host disease. Nature Communications, 2020, 11, 2246.	5.8	20
412	T-cell clones of uncertain significance are highly prevalent and show close resemblance to T-cell large granular lymphocytic leukemia. Implications for laboratory diagnostics. Modern Pathology, 2020, 33, 2046-2057.	2.9	40
413	High frequency of STAT3 gene mutations in Tâ€cell receptor (TCR)Î³Î± type Tâ€cell large granular lymphocytic leukaemia: implications for molecular diagnostics. British Journal of Haematology, 2020, 190, e301-e304.	1.2	5
414	Genetic and phenotypic characterization of indolent T-cell lymphoproliferative disorders of the gastrointestinal tract. Haematologica, 2020, 105, 1895-1906.	1.7	46
415	Identification of a <i>miR-146b</i>-Fas ligand axis in the development of neutropenia in T large granular lymphocyte leukemia. Haematologica, 2020, 105, 1351-1360.	1.7	28
416	A case of Î³Î± T-cell large granular lymphocytic leukemia due to a chronic active Epstein-Barr virus infection in systemic lupus erythematosus. Clinical Immunology, 2020, 214, 108378.	1.4	2
417	Sphingosine kinaseâ€2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mclâ€1. British Journal of Haematology, 2020, 190, 405-417.	1.2	19

#	ARTICLE	IF	CITATIONS
418	Insights Into Genetic Landscape of Large Granular Lymphocyte Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 152.	1.3	40
419	Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy. <i>European Journal of Medicinal Chemistry</i> , 2020, 201, 112428.	2.6	17
420	T-cell and NK-cell neoplasms of the gastrointestinal tract – recurrent themes, but clinical and biological distinctions exist. <i>Haematologica</i> , 2020, 105, 1760-1762.	1.7	6
421	Phenocopies of inborn errors of immunity. , 2020, , 143-149.		0
422	Refractory celiac disease type II: An atypical case highlighting limitations of the current classification system. <i>Hematological Oncology</i> , 2020, 38, 399-405.	0.8	6
423	Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. <i>Leukemia Research</i> , 2020, 90, 106299.	0.4	14
424	Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 103-112.	1.2	42
425	Somatic mutations and T-cell clonality in patients with immunodeficiency. <i>Haematologica</i> , 2020, 105, 2757-2768.	1.7	18
426	Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation. <i>Cancers</i> , 2020, 12, 126.	1.7	2
427	High Incidence of Clonal CD8+ T-cell Proliferation in Non-malignant Conditions May Reduce the Significance of T-cell Clonality Assay for Differential Diagnosis in Oncohematology. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 203-208.	0.2	8
428	Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2020, 189, 318-322.	1.2	10
429	Cancer Tendency in a Patient with ZNF341 Deficiency. <i>Journal of Clinical Immunology</i> , 2020, 40, 534-538.	2.0	3
430	Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. <i>Cancers</i> , 2020, 12, 240.	1.7	49
431	Identification of novel regulators of STAT3 activity. <i>PLoS ONE</i> , 2020, 15, e0230819.	1.1	12
432	Peripheral T cell lymphomas: from the bench to the clinic. <i>Nature Reviews Cancer</i> , 2020, 20, 323-342.	12.8	74
433	A high definition picture of somatic mutations in chronic lymphoproliferative disorder of natural killer cells. <i>Blood Cancer Journal</i> , 2020, 10, 42.	2.8	22
434	Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature. <i>Seminars in Cancer Biology</i> , 2022, 80, 157-182.	4.3	92
435	Clinical outcomes in T-cell large granular lymphocytic leukaemia: prognostic factors and treatment response. <i>British Journal of Haematology</i> , 2021, 192, 484-493.	1.2	6

#	ARTICLE	IF	CITATIONS
436	Spleen: Development, anatomy and reactive lymphoid proliferations. <i>Seminars in Diagnostic Pathology</i> , 2021, 38, 112-124.	1.0	16
437	Biological and genetic landscape of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). <i>European Journal of Surgical Oncology</i> , 2021, 47, 942-951.	0.5	13
438	Analysis of a single-institution cohort of patients with Felty's syndrome and T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. <i>Rheumatology International</i> , 2021, 41, 147-156.	1.5	13
439	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. <i>Modern Pathology</i> , 2021, 34, 904-921.	2.9	11
440	<scp>CD8</scp>-positive cutaneous lymphoproliferation associated with large granular lymphocyte leukemia in a patient with X-linked agammaglobulinemia. <i>Journal of Cutaneous Pathology</i> , 2021, 48, 567-571.	0.7	3
441	Phenocopies of inborn errors of immunity. , 2021, , 317-344.		0
442	Large Granular Lymphocyte Leukemia. <i>Hematologic Malignancies</i> , 2021, , 231-246.	0.2	0
443	Clonal hematopoiesis in adult pure red cell aplasia. <i>Scientific Reports</i> , 2021, 11, 2253.	1.6	12
444	Clinical and Immunological Heterogeneity in Japanese Patients with Gain-of-Function Variants in STAT3. <i>Journal of Clinical Immunology</i> , 2021, 41, 780-790.	2.0	10
445	Novel invariant features of Good syndrome. <i>Leukemia</i> , 2021, 35, 1792-1796.	3.3	11
446	Life-Saving, Dose-Adjusted, Targeted Therapy in a Patient with a STAT3 Gain-of-Function Mutation. <i>Journal of Clinical Immunology</i> , 2021, 41, 807-810.	2.0	10
447	The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 603.	1.8	120
448	Managing Relapsed Disease in Peripheral T-Cell Lymphoma: Highlights From SOHO 2020. <i>Journal of the Advanced Practitioner in Oncology</i> , 2021, 12, 27-29.	0.2	0
450	Emerging Role of T-cell Receptor Constant Î² Chain-1 (TRBC1) Expression in the Flow Cytometric Diagnosis of T-cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1817.	1.8	27
452	Hallmarks of the aging Tâ€cell system. <i>FEBS Journal</i> , 2021, 288, 7123-7142.	2.2	70
453	Clinical Utility of Targeted Next-Generation Sequencing in the Evaluation of Low-Grade Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2021, 156, 433-444.	0.4	5
454	Frequent somatic <i>TET2</i> mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. <i>Blood</i> , 2021, 138, 662-673.	0.6	30
455	Germline STAT3 gain-of-function mutations in primary immunodeficiency: Impact on the cellular and clinical phenotype. <i>Biomedical Journal</i> , 2021, 44, 412-421.	1.4	25

#	ARTICLE	IF	CITATIONS
456	JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. <i>Blood Cancer Journal</i> , 2021, 11, 56.	2.8	3
457	Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia. <i>Leukemia</i> , 2021, 35, 1365-1379.	3.3	41
458	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 832-840.	2.1	0
460	How I manage acquired pure red cell aplasia in adults. <i>Blood</i> , 2021, 137, 2001-2009.	0.6	29
461	Altered Spectrum of Lymphoid Neoplasms in a Single-Center Cohort of Common Variable Immunodeficiency with Immune Dysregulation. <i>Journal of Clinical Immunology</i> , 2021, 41, 1250-1265.	2.0	15
463	Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas. <i>Seminars in Hematology</i> , 2021, 58, 78-84.	1.8	2
464	Mutations in STAT3 and TTN Associated with Clinical Outcomes in Large Granular Lymphocyte Leukemia. , 2021, , .		0
465	Large granular lymphocytic leukemia – A retrospective study of 319 cases. <i>American Journal of Hematology</i> , 2021, 96, 772-780.	2.0	26
466	Discovery of Pyrrole-imidazole Polyamides as PD-L1 Expression Inhibitors and Their Anticancer Activity via Immune and Nonimmune Pathways. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6021-6036.	2.9	9
467	Somatic Mutations in –Benign–Disease. <i>New England Journal of Medicine</i> , 2021, 384, 2039-2052.	13.9	111
468	MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. <i>Haematologica</i> , 2021, 106, 2682-2693.	1.7	44
469	Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors – A Strategy for Hematological Malignancies?. <i>Cancers</i> , 2021, 13, 2611.	1.7	15
470	JAK-STAT in Early Hematopoiesis and Leukemia. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 669363.	1.8	29
471	Hijacking the Pathway: Perspectives in the Treatment of Mature T-cell Leukemias. <i>HemaSphere</i> , 2021, 5, e573.	1.2	4
473	The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay. <i>Familial Cancer</i> , 2021, 20, 363-380.	0.9	4
474	STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. <i>Leukemia</i> , 2021, 35, 3430-3443.	3.3	20
475	Immunologic effects on the haematopoietic stem cell in marrow failure. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101276.	0.7	23
476	T-cell Large Granular Lymphocytic Leukemia Presenting as Post-transplant Lymphoproliferative Disorder: A Report of Two Cases and Literature Review. <i>Laboratory Medicine Online</i> , 2021, 11, 183-190.	0.0	0

#	ARTICLE	IF	CITATIONS
477	JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. <i>Carcinogenesis</i> , 2021, 42, 1411-1419.	1.3	30
478	Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. <i>Nature Communications</i> , 2021, 12, 5183.	5.8	26
479	The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia. <i>Biomedicines</i> , 2021, 9, 1051.	1.4	10
480	The Value of Flow Cytometry Clonality in Large Granular Lymphocyte Leukemia. <i>Cancers</i> , 2021, 13, 4513.	1.7	4
481	The JAK2 inhibitor TG101209 exhibits anti-tumor and chemotherapeutic sensitizing effects on Burkitt lymphoma cells by inhibiting the JAK2/STAT3/c-MYB signaling axis. <i>Cell Death Discovery</i> , 2021, 7, 268.	2.0	4
482	Trefoil Factor 3 Inhibits Thyroid Cancer Cell Progression Related to IL-6/JAK/STAT3 Signaling Pathway. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-11.	0.5	3
483	Discovery of Novel Polycyclic Polyprenylated Acylphloroglucinols from the Fruits of <i>Garcinia xanthochymus</i> as Antitumor Agents by Suppressing the STAT3 Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10365.	1.8	5
484	Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease. <i>Cancers</i> , 2021, 13, 4418.	1.7	11
485	Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 717388.	2.2	23
486	The anti-parallel dimer binding interface in STAT3 transcription factor is required for the inactivation of cytokine-mediated signal transduction. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 119118.	1.9	4
487	Targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential. <i>Biochemical Pharmacology</i> , 2021, 193, 114760.	2.0	42
488	Single-Antibody Evaluation of T-Cell Receptor β Constant Chain Monotypia by Flow Cytometry Facilitates the Diagnosis of T-Cell Large Granular Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 2021, 156, 139-148.	0.4	15
489	Mature T- and NK-Cell Neoplasms. , 2021, , 377-401.		0
490	Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas. <i>Endocrine Journal</i> , 2021, 68, 1143-1153.	0.7	4
491	Linking the KIR phenotype with <i>STAT3</i> and <i>TET2</i> mutations to identify chronic lymphoproliferative disorders of NK cells. <i>Blood</i> , 2021, 137, 3237-3250.	0.6	32
492	STAT3 and STAT5B mutations have unique distribution in T-cell large granular lymphocyte proliferations and advanced myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2021, 62, 1506-1509.	0.6	6
493	Protein Kinase CK2 and Dysregulated Oncogenic Inflammatory Signaling Pathways. , 2015, , 259-280.		2
494	Laboratory Workup of Lymphoma in Adults. <i>American Journal of Clinical Pathology</i> , 2021, 155, 12-37.	0.4	9

#	ARTICLE	IF	CITATIONS
495	Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology American Society of Hematology Education Program, 2012, 2012, 652-659.	0.9	53
496	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. Blood, 2020, 135, 360-370.	0.6	80
497	Methotrexate Is a JAK/STAT Pathway Inhibitor. PLoS ONE, 2015, 10, e0130078.	1.1	123
498	Concurrent Mutations in ATM and Genes Associated with Common $\hat{\beta}$ Chain Signaling in Peripheral T Cell Lymphoma. PLoS ONE, 2015, 10, e0141906.	1.1	20
499	Flow Cytometric Immunophenotyping Is Sensitive for the Early Diagnosis of De Novo Aggressive Natural Killer Cell Leukemia (ANKL): A Multicenter Retrospective Analysis. PLoS ONE, 2016, 11, e0158827.	1.1	9
500	Dysregulation of the IFN- $\hat{\beta}$ -STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS ONE, 2018, 13, e0193429.	1.1	15
501	Methotrexate therapy of T-cell large granular lymphocytic leukemia impact of STAT3 mutation. Oncotarget, 2016, 7, 61419-61425.	0.8	14
502	Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget, 2014, 5, 2131-2148.	0.8	43
503	<i>STAT3</i> mutation impacts biological and clinical features of T-LGL leukemia. Oncotarget, 2017, 8, 61876-61889.	0.8	67
504	Large granular lymphocytosis after transplantation. Oncotarget, 2017, 8, 81697-81708.	0.8	8
505	A guilt-by-association mutation network in LGL leukemia. Oncotarget, 2017, 8, 93299-93300.	0.8	3
506	Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget, 2017, 8, 97516-97527.	0.8	28
507	STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma. Oncotarget, 2018, 9, 16792-16806.	0.8	27
508	Genetic landscape of T- and NK-cell post-transplant lymphoproliferative disorders. Oncotarget, 2016, 7, 37636-37648.	0.8	46
509	Ailanthone: A novel potential drug for treating human cancer (Review). Oncology Letters, 2020, 20, 1489-1503.	0.8	15
510	Clinical application of genomic aberrations in adult T-cell leukemia/lymphoma. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 66-72.	0.3	9
511	STAT3 Signaling in Cancer. Journal of Cancer Therapy, 2015, 06, 709-726.	0.1	22
512	Laboratory Workup of Lymphoma in Adults: Guideline From the American Society for Clinical Pathology and the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2021, 145, 269-290.	1.2	9

#	ARTICLE	IF	CITATIONS
513	NCCN Guidelines Insights: T-Cell Lymphomas, Version 1.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1460-1467.	2.3	30
515	The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer. Journal of Personalized Medicine, 2021, 11, 1073.	1.1	7
516	Perturbed NK-cell homeostasis associated with disease severity in chronic neutropenia. Blood, 2022, 139, 704-716.	0.6	10
517	Precision diagnostics in lymphomas – Recent developments and future directions. Seminars in Cancer Biology, 2022, 84, 170-183.	4.3	13
518	Pancytopenia – a diagnostic challenge?. Memo - Magazine of European Medical Oncology, 2021, 14, 355-359.	0.3	2
519	Case Report: Deficiency of Adenosine Deaminase 2 Presenting With Overlapping Features of Autoimmune Lymphoproliferative Syndrome and Bone Marrow Failure. Frontiers in Immunology, 2021, 12, 754029.	2.2	11
520	Abstract 3164: Somatic mutation analysis pipeline for exome-sequencing data identifies oncogenic STAT3 mutations in T-LGL leukemia.. , 2013, , .		0
521	Targeting the JAK/STAT Pathway in Cytotoxic T lymphocytes (CTL) by Next Generation Sequencing (NGS). Methods in Molecular Biology, 2014, 1186, 253-268.	0.4	1
522	A Rare Variant of Aggressive T-Cell Large Granular Lymphocyte Leukemia Associated With Hepatic Fibrosis and Trisomy 8: A Case Report and Literature Review. Journal of Hematology (Brossard,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 41		0
525	T-Cell Non-Hodgkin's Lymphomas. , 2016, , 1-28.		0
526	T-Cell Non-Hodgkin's Lymphomas. , 2017, , 1683-1710.		0
527	Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature. Oncotarget, 2017, 8, 32292-32297.	0.8	2
528	T-Cell Large Granular Lymphocytic Leukemia. , 2018, , 846-851.		0
529	Jak/STAT Signaling in Head and Neck Cancer. Current Cancer Research, 2018, , 155-184.	0.2	3
530	Lymphatische Neoplasien und ihre Manifestation im Knochenmark. , 2019, , 141-176.		0
532	Lymphomas. , 2020, , 253-315.		0
533	Indolent T-/NK-Cell Lymphoproliferative Disorders. , 2020, , 307-321.		0
534	Somatic <I>STAT3</I> mutations in CD8<sup>+</sup> T cells of healthy blood donors carrying human T-cell leukemia virus type 2. Haematologica, 2022, 107, 550-554.	1.7	11

#	ARTICLE	IF	CITATIONS
535	Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. <i>Haematologica</i> , 2022, 107, 201-210.	1.7	12
536	T-Cell Large Granular Lymphocytic Leukemia. <i>Encyclopedia of Pathology</i> , 2020, , 485-488.	0.0	0
537	Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?. <i>Translational Medicine @ UniSa</i> , 2014, 8, 4-11.	0.8	14
538	Ginkgetin induces apoptosis in 786-O cell line suppression of JAK2-STAT3 pathway. <i>Iranian Journal of Basic Medical Sciences</i> , 2016, 19, 1245-1250.	1.0	9
539	The Challenges of Precision Medicine and New Advances in Molecular Diagnostic Testing in Hematolymphoid Malignancies: Impact on the VHA. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2017, 34, S50-S61.	0.6	0
543	The non-leukemic T cell large granular lymphocytic leukemia variant with marked splenomegaly and neutropenia in the setting of rheumatoid arthritis - Felty syndrome and hepatosplenic T cell lymphoma mask. <i>American Journal of Blood Research</i> , 2021, 11, 227-237.	0.6	3
544	A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. <i>Blood</i> , 2021, 138, 2828-2837.	0.6	65
545	Structural and utational nalysis of ember-specific STAT unctions. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2022, 1866, 130058.	1.1	3
546	Guidelines for the management of mature Tâ€and natural killerâ€cell lymphomas (excluding cutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 196, 507-522.	1.2	12
547	Phenocopies of Inborn Errors of Immunity. , 2021, , .		0
548	Overactive STAT3 Drives Accumulation of Disease-Associated CD21 ^{low} B Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
549	High-Sensitive TRBC1-Based Flow Cytometric Assessment of T-Cell Clonality in TÎ±Î²-Large Granular Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 408.	1.7	10
550	RUNX1-CBFÎ² Complex Modulates lncRNA PRADX Transcription, Activates Stat3 Pathway and Energy Metabolism Via Recruitment of H3K27me3 in Mesenchymal Glioblastoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
551	Case Report: Large Granular Lymphocyte Leukemia (LGLL)â€A Case Series of Challenging Presentations. <i>Frontiers in Oncology</i> , 2021, 11, 775313.	1.3	3
552	Clinicopathologic and Genetic Features of Primary T-cell Lymphomas of the Central Nervous System. <i>American Journal of Surgical Pathology</i> , 2022, 46, 486-497.	2.1	2
553	Genomic landscape of TCRÎ±Î² and TCRÎ³Î´ T-large granular lymphocyte leukemia. <i>Blood</i> , 2022, 139, 3058-3072.	0.6	24
554	The antimicrobial drug pyrimethamine inhibits STAT3 transcriptional activity by targeting the enzyme dihydrofolate reductase. <i>Journal of Biological Chemistry</i> , 2022, 298, 101531.	1.6	16
555	Recent advances in T-cell lymphoid neoplasms. <i>Experimental Hematology</i> , 2022, 106, 3-18.	0.2	9

#	ARTICLE	IF	CITATIONS
556	Toward a Better Classification System for NK-LGL Disorders. <i>Frontiers in Oncology</i> , 2022, 12, 821382.	1.3	2
558	Common Variable Immunodeficiency-Associated Cancers: The Role of Clinical Phenotypes, Immunological and Genetic Factors. <i>Frontiers in Immunology</i> , 2022, 13, 742530.	2.2	14
559	Identification of novel STAT5B mutations and characterization of TCR β signatures in CD4+ T-cell large granular lymphocyte leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 31.	2.8	15
560	Isolated anemia in patients with large granular lymphocytic leukemia (LGL). <i>Blood Cancer Journal</i> , 2022, 12, 30.	2.8	4
561	Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment. <i>Current Oncology Reports</i> , 2022, 24, 633-644.	1.8	2
562	Persistent Large Granular Lymphocyte Clonal Expansions: “The Root of Many Evils” And of Some Goodness. <i>Cancers</i> , 2022, 14, 1340.	1.7	8
563	Indolent T- and NK-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract: Current Understanding and Outstanding Questions. <i>Hemato</i> , 2022, 3, 219-231.	0.2	1
564	Cytokines in the Pathogenesis of Large Granular Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 2022, 12, 849917.	1.3	8
565	STAT3 Role in T-Cell Memory Formation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2878.	1.8	10
566	Curcumin as a Potential Therapeutic Agent in Certain Cancer Types. <i>Cureus</i> , 2022, 14, e22825.	0.2	7
567	JAK-STAT core cancer pathway: An integrative cancer interactome analysis. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 2049-2062.	1.6	32
568	Longitudinal study of 2 patients with cyclic thrombocytopenia, <i>STAT3</i> and <i>MPL</i> mutations. <i>Blood Advances</i> , 2023, 7, 190-194.	2.5	5
569	T-cell large granular lymphocytic leukaemia with atypical immunophenotypes: A single-centre retrospective analysis of 17 cases. <i>British Journal of Haematology</i> , 2022, , .	1.2	0
570	Have we reached a molecular era in myelodysplastic syndromes?. <i>Hematology American Society of Hematology Education Program</i> , 2021, 2021, 418-427.	0.9	23
571	The Diverse Roles of $\gamma\delta$ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. <i>Cancers</i> , 2021, 13, 6212.	1.7	13
572	Upadacitinib as Novel Treatment for Rheumatoid Arthritis with T-Cell Granular Lymphocytic Leukemia: A Case Report and Narrative Review. <i>Journal of Clinical Rheumatology and Immunology</i> , 2022, 22, 22-30.	0.4	2
573	CD8+ cell somatic mutations in multiple sclerosis patients and controls” Enrichment of mutations in STAT3 and other genes implicated in hematological malignancies. <i>PLoS ONE</i> , 2021, 16, e0261002.	1.1	15
574	Allogeneic Bone Marrow Transplant as a Cure for Refractory T-Cell Large Granular Lymphocytic Leukemia in an Adolescent. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, 44, e960-e963.	0.3	2

#	ARTICLE	IF	CITATIONS
575	JAK/STAT: a pathway through the maze of PTCL?. <i>Blood</i> , 2021, 138, 2747-2748.	0.6	1
576	miR-181a is a novel player in the STAT3-mediated survival network of TCR $\alpha\beta$ ⁺ CD8 ⁺ T large granular lymphocyte leukemia. <i>Leukemia</i> , 2022, 36, 983-993.	3.3	10
577	The Role of Janus Kinase/STAT3 Pathway in Hematologic Malignancies With an Emphasis on Epigenetics. <i>Frontiers in Genetics</i> , 2021, 12, 703883.	1.1	7
578	MicroRNAs and JAK/STAT3 signaling: A new promising therapeutic axis in blood cancers. <i>Genes and Diseases</i> , 2022, 9, 849-867.	1.5	13
581	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8 ⁺ T-cell large granular lymphocytic leukemia. <i>Nature Communications</i> , 2022, 13, 1981.	5.8	23
588	Large granular lymphocytic leukemia: a brief review.. <i>American Journal of Blood Research</i> , 2022, 12, 17-32.	0.6	0
589	lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy. <i>Frontiers in Oncology</i> , 2022, 12, 888922.	1.3	5
590	Case Report: First Report of T-Cell Large Granular Lymphocytic Leukemia With NPL-DHX9 Gene Fusion Successfully Treated With Cladribine: Clinical Experience and Literature Review. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
591	Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2022, 140, 1891-1906.	0.6	19
592	CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk. <i>Nature Genetics</i> , 2022, 54, 637-648.	9.4	13
593	Increased radiosensitivity and impaired DNA repair in patients with STAT3-LOF and ZNF341 deficiency, potentially contributing to malignant transformations. <i>Clinical and Experimental Immunology</i> , 2022, 209, 83-89.	1.1	2
594	Intersection Between Large Granular Lymphocyte Leukemia and Rheumatoid Arthritis. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	7
595	CD8-positive indolent T-Cell lymphoproliferative disorder of the gastrointestinal tract: A case report and review of literature. <i>World Journal of Clinical Cases</i> , 2022, 10, 4971-4984.	0.3	2
597	Evaluation of the putative lymphoma-associated point mutation D427H in the STAT3 transcription factor. <i>BMC Molecular and Cell Biology</i> , 2022, 23, .	1.0	0
598	Pathogenesis and Treatment of T-Large Granular Lymphocytic Leukemia (T-LGLL) in the Setting of Rheumatic Disease. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
599	Defining TCR $\alpha\beta$ ⁺ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation. <i>Nature Communications</i> , 2022, 13, .	5.8	7
600	Somatic mutations in acquired pure red cell aplasia. <i>Seminars in Hematology</i> , 2022, , .	1.8	4
601	Inclusion Body Myositis and Neoplasia: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7358.	1.8	5

#	ARTICLE	IF	CITATIONS
602	CHIPing away the progression potential of CHIP: A new reality in the making. <i>Blood Reviews</i> , 2023, 58, 101001.	2.8	6
603	Genomic profiling for clinical decision making in lymphoid neoplasms. <i>Blood</i> , 2022, 140, 2193-2227.	0.6	63
604	The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome. <i>Seminars in Hematology</i> , 2022, 59, 123-130.	1.8	7
605	Distinguishing STAT3/STAT5B Mutated Large Granular Lymphocyte Leukemia from Myeloid Neoplasms by Genetic Profiling. <i>Blood Advances</i> , 0, , .	2.5	4
607	Somatic mutations in "benign" blood diseases. <i>Seminars in Hematology</i> , 2022, 59, 121-122.	1.8	0
608	STAT3 mutations in "gray-zone" cases of T-cell large granular lymphocytic leukemia associated with autoimmune rheumatic diseases. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
609	Novel Germline TET2 Mutations in Two Unrelated Patients with Autoimmune Lymphoproliferative Syndrome-Like Phenotype and Hematologic Malignancy. <i>Journal of Clinical Immunology</i> , 2023, 43, 165-180.	2.0	3
610	TIGIT ^{hi} LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. <i>Blood</i> , 2023, 141, 1036-1046.	0.6	6
611	All that glitters is not LGL Leukemia. <i>Leukemia</i> , 2022, 36, 2551-2557.	3.3	8
612	Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12745.	1.8	0
613	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. <i>Biomedicines</i> , 2022, 10, 2628.	1.4	1
614	LGL Clonal Expansion and Unexplained Cytopenia: Two Clues Don't Make an Evidence. <i>Cancers</i> , 2022, 14, 5236.	1.7	3
615	Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 1081-1095.	1.5	31
616	Clinical Study of the Relationship between Sjögren Syndrome and T-Cell Large Granular Lymphocytic Leukemia: Single-Center Experience. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13345.	1.8	1
617	Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13392.	1.8	0
618	T cell aging as a risk factor for autoimmunity. <i>Journal of Autoimmunity</i> , 2023, 137, 102947.	3.0	3
619	Inside the stemness engine: Mechanistic links between deregulated transcription factors and stemness in cancer. <i>Seminars in Cancer Biology</i> , 2022, 87, 48-83.	4.3	10
620	Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on related heterocycle-fused naphthoquinones for cancer therapy. <i>New Journal of Chemistry</i> , 2022, 47, 156-166.	1.4	0

#	ARTICLE	IF	CITATIONS
621	High prevalence of low-allele-fraction somatic mutations in STAT3 in peripheral blood CD8+ cells in multiple sclerosis patients and controls. PLoS ONE, 2022, 17, e0278245.	1.1	2
622	Identification of novel NFKB1 and ICOS frameshift variants in patients with COVID-19. Clinical and Experimental Immunology, 2023, 13, .	1.1	0
623	Frequent somatic mosaicism in T lymphocyte subsets in individuals with and without multiple sclerosis. Frontiers in Immunology, 2023, 13, .	2.2	3
624	STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation. Immunity, 2022, 55, 2386-2404.e8.	6.6	20
625	The JAK-STAT-SOCS Signaling Cascade. , 2016, , 162-179.		0
627	The ups and downs of STAT3 function: too much, too little and human immune dysregulation. Clinical and Experimental Immunology, 2023, 212, 107-116.	1.1	6
628	SBNO2 is a critical mediator of STAT3-driven hematological malignancies. Blood, 2023, 133, .	0.6	0
629	Plasmablastic lymphoma: from genetics to treatment. Leukemia and Lymphoma, 2023, 64, 799-807.	0.6	0
630	An update on genetic aberrations in T-cell neoplasms. Pathology, 2023, 55, 287-301.	0.3	4
631	Case Report: mRNA vaccination-mediated STAT3 overactivation with agranulocytosis and clonal T-LGL expansion. Frontiers in Immunology, 2023, 14, .	2.2	1
632	Autoimmune Neutropenias: Update on Clinical and Biological Features in Children and Adults. HemaSphere, 2023, 7, e814.	1.2	5
633	Dynamics of Age- versus Therapy-Related Clonal Hematopoiesis in Long-term Survivors of Pediatric Cancer. Cancer Discovery, 2023, 13, 844-857.	7.7	12
634	Prognostic analysis of smoldering ATLL with skin eruptions based on genomic aberrations. Journal of Dermatological Science, 2023, 109, 80-88.	1.0	0
635	Not all LGL leukemias are created equal. Blood Reviews, 2023, 60, 101058.	2.8	4
636	A multifaceted disease: The stats of STAT3 GOF. Journal of Allergy and Clinical Immunology, 2023, 151, 901-903.	1.5	0
637	T-cell large granular lymphocytic leukemia in the setting of rheumatoid arthritis. , 2023, , 221-231.		0
638	BP-102 exerts antitumor effects on T cell acute lymphoblastic leukemia cells by suppressing the JAK2/STAT3-Myc signaling pathway. Experimental and Therapeutic Medicine, 2023, 25, .	0.8	0
639	T-large granular lymphocytic leukemia. Blood Research, 2023, 58, S52-S57.	0.5	4

#	ARTICLE	IF	CITATIONS
640	A case report of T-LGL leukemia-associated pure red cell aplasia harboring STAT3, TNFAIP3, and KMT2D mutation. <i>Translational Cancer Research</i> , 2023, .	0.4	0
641	Large granular lymphocyte leukemia: An indolent clonal proliferative disease associated with an array of various immunologic disorders. <i>Revue De Medecine Interne</i> , 2023, 44, 295-306.	0.6	1
645	Molecular mechanisms underlying transformation of large granular lymphocytic leukemia to high-grade T-cell lymphoma. <i>Leukemia</i> , 0, , .	3.3	1
647	Case Report: A rare case of CD20-positive T-cell large granular lymphocyte leukemia with renal cell carcinoma: a challenging diagnosis. , 0, 2, .		0
663	Plasmablastic Lymphoma. , 2023, , .		0
665	T-Cell Primary Splenic Lymphomas. , 2023, , .		0
669	Leukämie mit großen granulären Lymphozyten. , 2023, , 255-272.		0
671	The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders. <i>Blood Cancer Journal</i> , 2024, 14, .	2.8	0